FY2020 EPS Estimates for RioCan Real Estate Investment Trust (TSE:REI) Lifted by Analyst

Share on StockTwits

RioCan Real Estate Investment Trust (TSE:REI) – Stock analysts at National Bank Financial lifted their FY2020 earnings per share estimates for shares of RioCan Real Estate Investment Trust in a research report issued on Monday, August 5th. National Bank Financial analyst T. Woolley now forecasts that the company will post earnings per share of $1.84 for the year, up from their prior forecast of $1.82. National Bank Financial currently has a “Outperform Market Weight” rating on the stock.

RioCan Real Estate Investment Trust has a 52-week low of C$10.88 and a 52-week high of C$17.17.

RioCan Real Estate Investment Trust (TSE:REI) last released its quarterly earnings data on Tuesday, May 7th. The company reported C$0.64 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of C$0.43 by C$0.21. The company had revenue of C$324.14 million during the quarter.

See Also: Why do companies issue convertible shares?

Earnings History and Estimates for RioCan Real Estate Investment Trust (TSE:REI)

Receive News & Ratings for RioCan Real Estate Investment Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RioCan Real Estate Investment Trust and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

ACADIA Pharmaceuticals  Lifted to “Outperform” at Leerink Swann
ACADIA Pharmaceuticals Lifted to “Outperform” at Leerink Swann
Agios Pharmaceuticals  Lifted to Sell at BidaskClub
Agios Pharmaceuticals Lifted to Sell at BidaskClub
Axcelis Technologies  Upgraded to Buy by BidaskClub
Axcelis Technologies Upgraded to Buy by BidaskClub
Achillion Pharmaceuticals  Rating Lowered to Sell at ValuEngine
Achillion Pharmaceuticals Rating Lowered to Sell at ValuEngine
Apple  Price Target Cut to $165.00
Apple Price Target Cut to $165.00
ACADIA Pharmaceuticals  Upgraded to “Outperform” by Svb Leerink
ACADIA Pharmaceuticals Upgraded to “Outperform” by Svb Leerink


© 2006-2019 Ticker Report